| NCT ID | NCT06807840 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Influenza Human |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-01-27 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infection.
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Aged 18 years and older 4. Influenza positive test result performed within the University of Pennsylvania Health System Exclusion Criteria: 1. Known latex allergy 2. Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months 3. Pregnancy due to the volume of blood collected in this study 4. Treatment with immunoglobulin or another blood product within the 3 months prior to enrollment in this study 5. Any neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy ("active" is defined as having received treatment within the past 5 years) 6. Known acute or chronic medical condition that, in the opinion of the investigator or appropriate sub-investigator, would interfere with the evaluation of immune responses 7. Intends to donate blood during the study period 8. A known human immunodeficiency virus, hepatitis B, or hepatitis C infection 9. Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol 10. Prolonged inpatient hospitalization that disrupts or interferes with study procedures. 11. Weigh less than 110lbs
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06807840 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Influenza Human. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06807840 currently recruiting?
Yes, NCT06807840 is actively recruiting participants. Contact the research team at hensley@pennmedicine.upenn.edu for enrollment information.
Where is the NCT06807840 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06807840 clinical trial?
NCT06807840 is sponsored by University of Pennsylvania. The trial plans to enroll 50 participants.